The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008
Open accessAbstract
BACKGROUND: In the current study, the authors attempted to describe the incidence, most common sites, and mortality of second primary malignancies among survivors of common cancers. METHODS: The authors identified patients aged ≥18 years who were diagnosed with a primary malignancy from the 10 most common cancer sites (prostate, breast, lung, colon, rectum, bladder, uterus, kidney, melanoma, and non‐Hodgkin lymphoma) between 1992 and 2008 from Surveillance, Epidemiology, and End Results data. Factors associated with the incidence of second primary malignancies were explored using bivariable and multivariable models, and mortality attributable to first and second primary malignancies was examined. RESULTS: A cohort of 2,116,163 patients was identified, 170,865 of whom (8.1%) developed a second primary malignancy. Survivors of bladder cancer had the highest risk of developing a second cancer. In a multivariable model controlling for age, race, tumor grade, stage of disease, marital status, educational level, and income, a history of non‐Hodgkin lymphoma (hazard ratios of 2.70 and 2.88, respectively, for men and women) and bladder cancer (hazard ratios of 1.88 and 1.66, respectively, for men and women) predicted the highest risk of developing a second cancer. For patients with 2 incident cancers, 13% died of their initial cancer, but greater than one‐half (55%) died of their second primary malignancy. Lung cancer was the cause of death in 12% of patients with 2 incident cancers. CONCLUSIONS: Nearly 1 in 12 patients diagnosed with a common cancer developed a second malignancy, the most common of which was lung cancer. Greater than one‐half of patients with 2 incident cancers died of their secondary malignancy. The findings from the current study may inform care strategies among cancer survivors. Cancer 2016;122:3075‐3086. © 2016 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,853
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,775
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064
American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography
Saslow, D., Boetes, C., Burke, W., Harms, S., Leach, M. O., Lehman, C. D., Morris, E., Pisano, E., Schnall, M., Sener, S., et al. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.2.75 · Cited by 2,637
Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2014) · Annals of Internal Medicine · doi:10.7326/m13-2771 · Cited by 2,632
Burke, W. (1997) · JAMA · doi:10.1001/jama.277.12.997 · Cited by 955 · cited 1×
“For example, those with BRCA1 or BRCA2 mutations are at risk of developing multiple neoplasms and are candidates for screening with annual breast magnetic resonance imaging, 30 as well as for ovarian cancer screening.”
BackgroundSecond Cancers Among 40 576 Testicular Cancer Patients: Focus on Long-term Survivors
Travis, L. B., Fosså, S. D., Schonfeld, S. J., McMaster, M. L., Lynch, C. F., Storm, H., Hall, P., Holowaty, E., Andersen, A., Pukkala, E., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji278 · Cited by 823
de Moor, J. S., Mariotto, A. B., Parry, C., Alfano, C. M., Padgett, L., Kent, E. E., Forsythe, L., Scoppa, S., Hachey, M., & Rowland, J. H. (2013) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-12-1356 · Cited by 670
Lung Cancer Following Chemotherapy and Radiotherapy for Hodgkin's Disease
Travis, L. B. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.3.182 · Cited by 562
Humphrey, L. L., Deffebach, M., Pappas, M., Baumann, C., Artis, K., Mitchell, J. P., Zakher, B., Fu, R., & Slatore, C. G. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-6-201309170-00690 · Cited by 534
Cited by
CAMPBELL, K. L., WINTERS-STONE, K. M., WISKEMANN, J., MAY, A. M., SCHWARTZ, A. L., COURNEYA, K. S., ZUCKER, D. S., MATTHEWS, C. E., LIGIBEL, J. A., GERBER, L. H., et al. (2019) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000002116 · Cited by 2,988
Multiple primary tumours: challenges and approaches, a review
Vogt, A., Schmid, S., Heinimann, K., Frick, H., Herrmann, C., Cerny, T., & Omlin, A. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000172 · Cited by 628
Adams, S. J., Stone, E., Baldwin, D. R., Vliegenthart, R., Lee, P., & Fintelmann, F. J. (2023) · The Lancet · doi:10.1016/s0140-6736(22)01694-4 · Cited by 467
Liu, Y.-Q., Wang, X.-L., He, D.-H., & Cheng, Y.-X. (2021) · Phytomedicine · doi:10.1016/j.phymed.2020.153402 · Cited by 259
Metadata
- Authors
- Donin, N., Filson, C., Drakaki, A., Tan, H., Castillo, A., Kwan, L., Litwin, M., & Chamie, K.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2016-07-05
- Volume
- 122
- Issue
- 19
- Pages
- 3075-3086
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2464386849
- Cited by
- 343
- References
- 27
- FWCI
- 19.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008. https://app.cochat.ai/papers/10.1002/cncr.30164
- The paper
- Donin, N., Filson, C., Drakaki, A., Tan, H., Castillo, A., Kwan, L., Litwin, M., & Chamie, K. (2016). Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008. Cancer. https://doi.org/10.1002/cncr.30164
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.